Oestrogen cream for menopausal skin is trending across Instagram and TikTok, with influencers applying prescription formulations to their faces. But does it actually work – and is it safe?
Walk through any menopause corner of Instagram or TikTok and you’ll see influencers dabbing “oestrogen cream” onto cheeks as if it’s the missing chapter in the skincare bible.
The most common version is not a purpose-made facial product at all, but prescription vaginal oestriol (or oestradiol) cream repurposed for the face. The logic is seductive, the before-and-afters are compelling, and the science is interesting, but far from bulletproof.
Dr Ginni Mansberg delves into the benefits, risks and evidence behind different forms of topical oestrogen products..
What happens to the skin during menopause?
Skin contains oestrogen receptors¹ and is a hormonally responsive organ. When oestrogen levels fall during menopause, several changes tend to follow: reduced dermal collagen and elastin², thinning of skin, increased dryness, slower wound healing, and impaired barrier function. ³
Clinically, patients often report “crepey” texture, fine lines appearing seemingly overnight, increased sensitivity, and dullness.⁴ So, the hypothesis makes sense: replace oestrogen locally, improve skin quality locally.
What topical oestrogens are people using?
Vaginal oestriol creams (off-label facial use)
This is the most popular “hack” online. These products are designed for vulvovaginal atrophy/genitourinary syndrome of menopause, not facial skin. Professional menopause guidelines discuss vaginal oestrogen use for GSM, but do not endorse facial application.
Evidence is limited, and dermatologists advise caution regarding long-term safety and consistent dosing.
Possible side effects include skin irritation and increased pigmentation.
Compounded “bioidentical” facial oestrogen preparations
Compounding can produce oestradiol/ oestriol creams intended for facial use.
The key issue is that compounded products vary in dose, penetration, stability, and quality control. ⁵
In the UK, these compounded preparations do not follow the same regulatory pathways as conventional hormone replacement therapy (HRT). This means there is no guarantee of quality, consistency, or potency in each batch.
Purpose-designed cosmeceutical analogues with “oestrogen-like” activity
One example is methyl estradiolpropanoate, designed to have local cutaneous effects with minimal systemic hormonal effects.⁶
They act as a "soft oestrogen" receptor activator, meaning it targets oestrogen receptors only in the skin to improve signs of ageing without introducing hormones into the bloodstream.
The studies of these are small, company sponsored, and of short duration.
Phytoestrogens (e.g., genistein/isoflavones)
These are not oestrogens, but plant-derived compounds that can interact with oestrogen receptors. ⁷
They mimic oestrogen, offering a natural, non-hormonal approach to managing menopausal skin changes like dryness, thinning, and loss of elasticity.
They sit in a different evidence and safety bucket to prescription hormones.
Evidence is not robust enough to recommend these products at this stage. ⁷
What does evidence say about oestrogen cream?
The clinical evidence is suggestive, mixed, and mostly small-scale. ⁸
Histologic and biochemical studies show that oestrogen can stimulate collagen, but the “where” matters. A notable JAMA Dermatology study found that short-term topical oestradiol stimulated collagen production in sun-protected skin (hip) but not in chronically sun-exposed sites. ⁹
Some clinical trials report improvements in wrinkles, thickness and hydration. ⁸
However, protocols differ. Many used compounded hormones, and none compared oestrogen preparations to retinoids. ⁸ Studies were small, short, and included a mix of peri-, pre- and postmenopausal women, making conclusions difficult.
Many combine oestrogen preparations with other cosmeceuticals, so confounding is an issue. ⁸ While biologically plausible with some benefit, the evidence is insufficient. ⁸
Risks of using vaginal oestrogen cream on the face
Risks were addressed in a 2026 review published in the Journal of the American Academy of Dermatology, with authors warning that we do not have long-term safety data.⁸
The researchers pointed to the risk of endometrial proliferation with daily long term use of topical oestrogen preparations. ⁸
Systemic absorption is expected with any transdermal product. Unopposed oestrogen raises the risk of endometrial cancer. ¹⁰
Another concern is pigmentation. Up to one-third of women taking oral contraceptive pills may develop melasma, and oestrogen exposure is known to trigger melasma. ¹
The JAAD authors raised pigmentation as a concern and noted that it is not routinely assessed as an endpoint in most studies, leaving the data patchy. ⁸
Is topical oestrogen suitable for treating menopausal skin?
For routine cosmetic anti-ageing, it’s not yet suitable.⁸
Topical oestrogens may improve certain skin parameters in some postmenopausal women.
However, clinical trials are small and short, results are mixed, and long-term safety data is limited.
Until better data arrives, the most defensible “skin in menopause” prescription remains gloriously unsexy but highly effective: daily sunscreen, a retinoid (as tolerated¹¹), pigment control where relevant¹¹, barrier repair, and lifestyle fundamentals that influence inflammation and glycation.¹¹
Influencers can keep their hacks; clinicians should keep their standards.
Dr Ginni Mansberg
Dr Ginni Mansberg is a GP, TV presenter, podcaster, author and columnist. She is a physician specialising in women’s health, menopause and all things skin.
She is also the co-founder and medical director of science-based cosmeceutical skincare brand, ESK.
You might also like to read:
References
[1] Sagili H.,Rajan S., Cutaneous manifestations of estrogen excess and deficiency, GREM Gynecological and Reproductive Endocrinology & Metabolism (2021); Volume 2 - 3/2021:162-167 doi: 10.53260/GREM.212035
[2] Rzepecki AK, Murase JE, Juran R, Fabi SG, McLellan BN. Estrogen-deficient skin: The role of topical therapy. Int J Womens Dermatol. 2019 Mar 15;5(2):85-90. doi: 10.1016/j.ijwd.2019.01.001. PMID: 30997378; PMCID: PMC6451761.
[3] Zouboulis, C. C., Blume-Peytavi, U., Kosmadaki, M., Roó, E., Vexiau-Robert, D., Kerob, D., & Goldstein, S. R. (2022). Skin, hair and beyond: the impact of menopause. Climacteric, 25(5), 434–442. https://doi.org/10.1080/13697137.2022.2050206
[4] Zomer HD and Cooke PS (2023) Targeting estrogen signaling and biosynthesis for aged skin repair. Front. Physiol. 14:1281071. doi: 10.3389/fphys.2023.1281071
[5] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. PMID: 35797481.
[6] Draelos ZD. A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females. J Drugs Dermatol. 2018 Nov 1;17(11):1186 - 1189. PMID: 30500138.
[7] Lephart ED. Bioactives for Estrogen-Deficient Skin: Topical and Oral Supplement Clinical Studies. A Narrative Review. Dermatol Ther (Heidelb). 2025 Jul;15(7):1681-1703. doi: 10.1007/s13555-025-01413-2. Epub 2025 May 7. PMID: 40329055; PMCID: PMC12126418.
[8] Farkas, Eliana et al. Topical estrogen for skin aging: A systematic review of safety and efficacy. Journal of the American Academy of Dermatology, Volume 94, Issue 1, 212 - 215
[9] Rittié L, Kang S, Voorhees JJ, Fisher GJ. Induction of Collagen by Estradiol: Difference Between Sun-Protected and Photodamaged Human Skin In Vivo. Arch Dermatol. 2008;144(9):1129–1140. doi:10.1001/archderm.144.9.1129
[10] Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014 Jul;142:83-9. doi: 10.1016/j.jsbmb.2013.05.001. Epub 2013 May 13. PMID: 23680641; PMCID: PMC3775978.
[11] Fabi SG, Firsowicz M, Kamrani P, Draelos ZD, Dayan SH. Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal & Menopausal Patient. J Cosmet Dermatol. 2026 Jan;
